Overview

* Exicure ( XCUR ) Q2 net loss widens to $2.6 mln from $0.6 mln yr ago

* Company's cash position declines to $7.9 mln from $12.5 mln end of 2024

* Exicure ( XCUR ) needs substantial financing to continue operations, per management

Outlook

* Company needs substantial financing to continue operations

* Exicure ( XCUR ) exploring strategic alternatives

* Exicure ( XCUR ) uncertain about obtaining additional financing

Result Drivers

* ACQUISITION IMPACT - Increased R&D and G&A expenses due to acquisition of GPCR Therapeutics USA Inc.

* CASH DECLINE - Cash position fell to $7.9 mln from $12.5 mln at end of 2024

* FINANCIAL NEEDS - Management states substantial financing needed to continue operations

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Net -$2.62

Income mln

Before

Tax

Q2 Net -$2.62

Income mln

Q2 $2.51

Operatin mln

g

Expenses

Q2 -$2.51

Operatin mln

g Income

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)